SCTX
Scribe Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
—
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Scribe Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
—
Top fund weight
—
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Scribe Therapeutics has 2 disclosed suppliers and 3 disclosed customers in SEC filings.
Scribe Therapeutics, Inc.
15.79
SentenceOn
November 7, 2022, we entered into a development and option agreement, or the Acuitas Development and Option Agreement, with Acuitas Therapeutics, Inc., as supplemented and amended from time to time, the Acuitas Agreement
SCTX S-1/Aaccession 0001193125-26-308330
SentenceOn September 25, 2018, we entered into an exclusive license agreement with the Regents of the University of California, or the Regents
SCTX S-1/Aaccession 0001193125-26-308330
SentenceWe have funded our operations to date primarily from proceeds received under collaboration and license agreements with Sanofi, Lilly and Biogen
SCTX S-1/Aaccession 0001193125-26-308330BIIB
SentenceSanofi has the right to terminate the 2023 Sanofi License Agreement with respect to a licensed product, licensed target or in its entirety for convenience
SentenceOn May 11, 2023, we entered into a license and
collaboration agreement, or the Lilly License Agreement, with Prevail Therapeutics, Inc., a wholly-owned subsidiary of Eli Lilly and Company, for research and development collaborations and granting to Prevail exclusive license rights under patents
and technology for certain products
SCTX S-1/Aaccession 0001193125-26-308330
Linked news
Expected move
No implied move.